High grade gliomas are malignant brain tumors with a median survival of under 16 months. Despite advances in treatment, which includes surgical resection followed by chemotherapy and radiation, this number has not increased much over the last decade. The success of immunotherapies in other cancers gives hope for such therapeutics in gliomas. This research utilized a publically available RNA sequencing data from 625 low-grade gliomas and 388 high-grade glioma samples from the Chinese Glioma Genome Atlas. Changes in gene expression between primary and recurrent tumors were analyzed as clinical trials are mostly conducted in the recurrent setting. The results indicated that the expression of several immune checkpoint molecules, like PD-1, PD-L1, CTLA4, and LAG3, did not change between primary and recurrent tumors. Conversely, the expression of OPN, B7-H3, TGF-Beta, and Galectin-3 significantly changed between primary and recurrent tumors and should be considered therapeutic for recurrent glioma patients. While the failure of several immunotherapies in clinical trials may be due to the low expression of molecules such as PD-1, there are currently trials underway for B7-H3 and TGF-Beta. In the future, clinical trials for gliomas should consider OPN and Galectin-3.